



**Mouse Anti-Human Programmed Death Ligand-1 Monoclonal Antibody Datasheet**

**Product Name:** mAb anti-Human PDL-1

**Clone No.:** 6A5

**Catalogue No.:** MO-L40044E

**Quantity:** 0.5 mg/vial

**Description:** Mouse monoclonal antibody (mAb) to human programmed death ligand-1 (PDL-1), or mouse mAb to B7H1, or mouse mAb to human CD274.

**Purification:** Protein G affinity purified

**Product Type:** Primary antibody

**Target Protein:** Human programmed death ligand-1 (PD-1), also known as B7H1 or CD274.

**Immunogen:** Human cell expressed recombinant PDL-1 (Phe19-Arg238) with poly-histidine tag at C-terminus.

**Fusion Myeloma:** Sp2/0-Ag14

**Specificity:** Reactive with human programmed death ligand-1 (PDL-1).

**Species Reactivity:** Human, others not tested.

**Host / Isotype:** Mouse, IgG1 Kappa

**Formulation:** Lyophilized from a solution in 0.01M PBS, pH 7.2

**Reconstitution:** Double distilled water is recommended to adjust the final concentration to 1.00mg/mL.

**Storage:** Store at -20°C. Avoid repeated freeze/thaw cycles after reconstitution.

**Research Area:** Immunosuppression. Cancer immunotherapy.

**Background:** Programmed Death Ligand-1 (PDL-1) is a

40KD transmembrane protein that can link with immune checkpoint protein Programmed Death-1 (PD-1) when T-cell receptors engage with its specific antigen. During T cell receptor signaling, the binding of PDL-1 with PD-1 transmits an inhibitory signals to IL-2 production and T cell proliferation. This inhibitory co-stimulation plays an important role in body's immune suppressive functions, such as self-tolerance, suppression of immune-rejection during pregnancy and allograft etc. Upregulation of PD-L1 was found to be associated with many cancer types and is believed to contribute to the immune evasion by cancer. For example, increased PDL-1 expression has been shown to be related to tumor aggressiveness and higher mortality in patients with renal cell carcinoma, and related to significantly poorer prognosis and lower intraepithelial CD8+ T-lymphocyte count in patients with ovarian cancer. Antibodies that block the PDL-1 /PD-1 pathway have been extensively studied in clinical trials as immunotherapies for cancer. Among them, Nivolumab and Pembrolizumab have been approved by FDA for treatment of melanoma and non-small cell lung cancer.

**Application:** The antibody reacts with PDL-1 in Indirect ELISA.

**References:** If research is published using this product, please inform Anogen in order to cite the reference on this datasheet. Anogen will provide one unit of product in the same category as gratitude.

**This product is for LABORATORY RESEARCH USE and further manufacture ONLY, and cannot be administered to human and animals for use in diagnostic and therapeutic procedures.**

**Manufactured by ANOGEN - A Division of YES Biotech Laboratories Ltd.**